The American Cancer Society published a breast cancer screening guideline that steers toward the middle course in deciding when mammography screening should start and how often it should be performed.
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
CT colonography and stool DNA failed to get on the list of preferred tools for screening for colorectal cancer. A draft guideline from the U.S. Preventive Services Task Force released Oct. 6 calls for using one of three strategies: Fecal immunochemical test or high-sensitivity guaiac-based fecal occult blood test every year; Flexible sigmoidoscopy every ten... […]
The Centers for Medicare and Medicaid Services appear to be executing a two-step strategy to shrink the $8 billion annual price tag of clinical diagnostic laboratory tests.
Congress must put an end to the emerging practice of “information blocking” by purveyors of electronic health record systems, American Society of Clinical Oncology urged at a Capitol Hill briefing.
NIH, NCI and FDA should receive budget increases of at least 7 percent a year, the 2015 Cancer Progress Report by the American Association for Cancer Research recommends.
After a courtroom victory against Amgen Inc. this summer, the last of the obstacles was removed for the first biosimilar agent—a white blood cell growth factor—to enter the U.S. market.
After years of turmoil and plunging morale at MD Anderson Cancer Center, the UT System took what observers describe as an unprecedented step—forming a Shared Governance Committee.
A Story in Mugshots: from left, Jerald Cobbs, former CPRIT chief commercialization officer; Texas Governor Rick Perry; and Travis County District Attorney Rosemary Lehmberg. The indictment of Texas Governor Rick Perry by a Travis County grand jury brings together two complex subplots: The controversy over the Cancer Prevention and Research Institute of Texas, which came into […]
After a decade of near-absence from the US market, the AstraZeneca drug Iressa (gefitinib) is back.
